1. Home
  2. CNM vs ABVX Comparison

CNM vs ABVX Comparison

Compare CNM & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core & Main Inc.

CNM

Core & Main Inc.

HOLD

Current Price

$54.14

Market Cap

10.9B

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$112.38

Market Cap

10.5B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNM
ABVX
Founded
1996
2013
Country
United States
France
Employees
N/A
67
Industry
Durable Goods
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
10.9B
10.5B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CNM
ABVX
Price
$54.14
$112.38
Analyst Decision
Buy
Buy
Analyst Count
11
12
Target Price
$61.91
$128.42
AVG Volume (30 Days)
1.9M
707.7K
Earning Date
03-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.94
N/A
Revenue
$7,441,000,000.00
N/A
Revenue This Year
$4.15
N/A
Revenue Next Year
$4.18
$0.22
P/E Ratio
$28.16
N/A
Revenue Growth
11.03
N/A
52 Week Low
$43.18
$4.77
52 Week High
$67.18
$148.83

Technical Indicators

Market Signals
Indicator
CNM
ABVX
Relative Strength Index (RSI) 43.18 37.41
Support Level $52.17 $107.99
Resistance Level $54.76 $131.27
Average True Range (ATR) 1.80 5.13
MACD -0.37 -1.46
Stochastic Oscillator 28.52 19.93

Price Performance

Historical Comparison
CNM
ABVX

About CNM Core & Main Inc.

Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: